Osteosarcoma: anatomic and histologic variants.

Department of Pathology, University of Alabama at Birmingham and the Birmingham Veterans Affairs Medical Center 35233, USA.
American Journal of Clinical Pathology (Impact Factor: 3.01). 05/2006; 125(4):555-81. DOI: 10.1309/UC6K-QHLD-9LV2-KENN
Source: PubMed

ABSTRACT Osteosarcoma is the most common primary tumor of bone, yet its absolute incidence among malignant tumors is low. Within its strict histologic definition, osteosarcoma comprises a family of lesions with considerable diversity in histologic features and grade. Its prognosis is dependent not only on these parameters, but also on its anatomic site. It may occur inside the bones (in the intramedullary or intracortical compartment), on the surfaces of bones, and in extraosseous sites. Information of diagnostic or prognostic significance has not been elucidated from studies of its cytogenetics. This review summarizes the anatomic and histologic variations of osteosarcoma and offers a schema for its subclassification.

1 Bookmark
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Osteosarcoma (OS) is the most common primary malignant bone tumor and prevalently occurs in the second decade of life. Etoposide, a chemotherapeutic agent used in combined treatments of recurrent human OS, belongs to the topoisomerase inhibitor family and causes DNA breakage. In this study we evaluated the cascade of events determined by etoposide-induced DNA damage in OS cell lines with different p53 status focusing on methylation status and expression of miR-34a that modulate tumor cell growth and cell cycle progression. Wild-type p53 U2-OS cells and U2-OS cells expressing dominant-negative form of p53 (U2- OS175) were more sensitive to etoposide than p53-deficient MG63 and Saos-2 cells, showing increased levels of unmethylated miR-34a, reduced expression of CDK4 and cell cycle arrest in G1 phase. In contrast, MG63 and Saos-2 cell lines presented aberrant methylation of miR-34a promoter gene with no miR-34a induction after etoposide treatment, underlining the close connection between p53 expression and miR-34a methylation status. Consistently, in p53siRNA transfected U2-OS cells we observed loss of miR-34a induction after etoposide exposure associated with a partial gain of gene methylation and cell cycle progress towards G2/M phase. Our results suggest that the open and unmethylated conformation of the miR-34a gene may be regulated by p53 able to bind the gene promoter. In conclusion, cell response to etoposide-induced DNA damage was not compromised in cells with dominant-negative p53 expression.
    PLoS ONE 12/2014; 9(12):e114757. DOI:10.1371/journal.pone.0114757 · 3.53 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Osteosarcoma (OS) is the most prevalent primary malignant bone tumor in children and young adults, its complex etiology involving a combination of environmental and genetic factors. MicroRNA (miRNA) is a short, non‑coding regulatory RNA molecule that represses gene expression by imperfectly base‑pairing to the 3' untranslated region of target mRNAs. Evidence has shown that alterations in the expression of miRNA are involved in the initiation, progression, and metastasis of human cancers. It is believed that miRNAs function both as tumor suppressors and oncogenes during cancer development. In the present study, three tumor-associated miRNAs (miR‑21, miR‑34a and miR‑146a) coding regions were screened in Chinese‑Han OS patients. A G>A variation in the pre‑miR‑34a coding region was found to be associated with higher OS morbidity. By detecting the mature miR‑34a expression in cells transfected with pre‑miR‑34a expression vectors of different genotypes using quantitative polymerase chain reaction, it was demonstrated that the G>A variation reduced miR‑34a expression in vitro. This was in accordance with the data collected from tumor tissue and patient serum samples. Subsequently, a dual‑luciferase reporter assay and western blot analysis were used to detect the site variation effect on the expression of c‑Met, a target gene of miR‑34a. The G>A variation downregulated the suppression of c‑Met in two OS cell lines. Furthermore, it was found that reduced miR‑34a expression decreased the suppression of OS cell proliferation in vitro. In conclusion, the present study established the association between miR‑34a and the risk of suffering OS in a Chinese Han population by identifying one functional single nucleotide polymorphism site in pre‑miR‑34a. These findings may give insight into the mechanism of OS development and create an opportunity to approach the diagnosis and treatment of OS.
    Molecular Medicine Reports 09/2014; DOI:10.3892/mmr.2014.2582 · 1.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Multifocal osteosarcoma is diagnosed when there are two or more lesions in the skeleton without presence of pulmonary metastases. It is further classified as synchronous type when the patient is demonstrated to have more than one lesion simultaneously at presentation and is known as Synchronous Multifocal Osteogenicsarcoma (MOGS). We report a case of synchronous MOGS showing its multimodality imaging findings including nuclear scan findings with pathological correlation.
    07/2014; 29(3):185-8. DOI:10.4103/0972-3919.136591

Full-text (2 Sources)

Available from
May 17, 2014